DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Bladder Cancer
- Colorectal Cancer
- Esophageal Cancer
- Head and Neck Cancer
- Kidney Cancer
- Lung Cancer
- Pancreas Cancer
- Stomach Cancer
- Type
- Observational
- Design
- Observational Model: Case-ControlTime Perspective: Prospective
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is confirmed. At enrollment, subjects will have blood specimens collected (~40 mL) and 12 months post-enrollment their medical records will be reviewed.
Subjects will be enrolled into the DELFI-L101 study after informed consent and eligibility is confirmed. At enrollment, subjects will have blood specimens collected (~40 mL) and 12 months post-enrollment their medical records will be reviewed.
Tracking Information
- NCT #
- NCT04825834
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Peter Mazzone, MD, MPH The Cleveland Clinic
Get Well Soon